Relationship of increased serum brain natriuretic peptide levels with hepatic failure, portal hypertension and treatment in patients with cirrhosis

B-type natriuretic peptide and cirrhosis progression

“…In cirrhotic cardiomyopathy, beta adrenergic receptor and plasma membrane dysfunction are observed in addition to an increase in intracardiac volume; therefore, diuretics and beta-blockers likely decrease BNP levels in patients with decompensated heart failure (Johnson et al, 2002) by improving hemodynamic parameters and the left ventricular ejection fraction (Møller and Henriksen, 2002;Fujimura et al, 2009), thus reducing intracardiac pressure and sodium retention and consequently decreasing the secretion of BNP. However, we draw the opposite conclusion in this study from our results than did Yilmaz et al (2010), who surmised that these findings might be a result of a selection bias, because the probable underlying cause of increased levels of BNP in patients using beta-blockers and diuretics might be that these patients were more likely to suffer from volume overload, and that these medications are usually given in these patients. However, the underlying cause of the increased BNP levels seen in patients with cirrhosis is still unknown.…”

Galactin-3 and brain natriuretic peptide versus conventional echocardiography in the early detection of cirrhotic cardiomyopathy

“…With respect to BNP levels between our three study groups, a statistically significant difference was observed and was higher in the patient groups (p<0.001); the levels increased with the severity of cirrhosis, and our results are in agreement with previous studies that showed BNP level to be significantly increased with degree of liver cirrhosis, liver failure, and portal hypertension (26,27).…”

Serum Pro – Brain Natriuretic Peptide (Pro - Bnp) in Patients With Cirrhosis : Relation to Cardiac Dysfunction and Severity of Disease

“…Patients with CTP class C are more likely to have higher pro-BNP levels compared to CTP class A and B. Similar observations were made by Yilmaz et al 26 and Ziada et al 27 We used a cut-off of 100 ng/ml given by FDA to find out its role as a predictor of cardiac dysfunction in patients with liver cirrhosis. It showed a high sensitivity of 97.36% and a low specificity of 46.08%.…”

“…Similar relation was noted by Yilmaz et al Patients with serum albumin <2.8 mg/dl are more likely to have higher mean pro-BNP levels. 26 We found a positive correlation (P value -0.001) between CTP class and pro-BNP levels. Patients with CTP class C are more likely to have higher pro-BNP levels compared to CTP class A and B.…”